TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial

NCT04531228 · clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Yunfei Yuan